Paul D. Smith

13.6k citations

120 papers · 7.5k indexed · 3 hit papers · h-index 45

Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism 9
Oncology top 1%
- Colorectal Cancer Treatments and Studies 15
Molecular Biology top 1%
- Melanoma and MAPK Pathways 31
- PI3K/AKT/mTOR signaling in cancer 18
- Epigenetics and DNA Methylation 11
Obstetrics and Gynecology top 2%
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 30
Pathology and Forensic Medicine
- Cancer Mechanisms and Therapy 13
Genetics
- Genetic Syndromes and Imprinting 7

Co-authors: Simon J. Cook Matthew J. Sale Elaine Kilgour Wolf Reik A. N. Brooks Christopher J. Caunt Wendy Dean Armelle Logié
Cited by: Cancer Research Oncology Molecular Biology
Journals: Chemical Reviews (1 paper)Proceedings of the National Academy of Sciences (2 papers)JAMA (1 paper)
Partner nations: United Kingdom United States France

In The Last Decade

Paul D. Smith

117 papers receiving 7.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Paul D. Smith

Since Specialization

Citations

This map shows the geographic impact of Paul D. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul D. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul D. Smith more than expected).

Fields of papers citing papers by Paul D. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul D. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul D. Smith. The network helps show where Paul D. Smith may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul D. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul D. Smith Line = papers co-authored together Paul D. Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance NAR Cancer ·Prasanna Channathodiyil,Kieron May,Anne Segonds-Pichon,Paul D. Smith,Simon J. Cook,Jonathan Houseley	2022	3
2	Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer Clinical Cancer Research ·Mariano Ponz‐Sarvisé,Vincenzo Corbo,Hervé Tiriac,Dannielle D. Engle,Kristopher K. Frese,Tobiloba E. Oni,Chang‐Il Hwang,Daniel Öhlund,Iok In Christine Chio,Lindsey A. Baker,Dea Filippini,Kevin Wright,Tashinga E. Bapiro,Pearl S. Huang,Paul D. Smith,Kenneth H. Yu,Duncan I. Jodrell,Youngkyu Park,David A. Tuveson	2019	41
3	MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy Cancer Research ·Mounia Beloueche‐Babari,Slawomir Wantuch,Teresa Casals Galobart,Markela Koniordou,Harold G. Parkes,Vaitha Arunan,Yuen‐Li Chung,Thomas R. Eykyn,Paul D. Smith,Martin O. Leach	2017	105
4	New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome Cancer Research ·Leah Wilson,Adam J. Linley,Dean E. Hammond,Fiona E. Hood,Judy M. Coulson,David J. MacEwan,Sarah J. Ross,Joseph R. Slupsky,Paul D. Smith,Patrick A. Eyers,Ian A. Prior	2017	117
5	Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Clinical Cancer Research ·Roz Brant,Alan Sharpe,Tom Liptrot,Jonathan R. Dry,Elizabeth A. Harrington,J. Carl Barrett,Nicky Whalley,Christopher J. Womack,Paul D. Smith,Darren Hodgson	2016	17
6	Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547 Molecular Cancer Therapeutics ·Oona Delpuech,Claire Rooney,Lorraine Mooney,Dawn Baker,Robert A. Shaw,Michael Dymond,Dennis Wang,Pei Zhang,Sarah Cross,Margaret H. Veldman-Jones,Joanne Wilson,Barry R. Davies,Jonathan R. Dry,Elaine Kilgour,Paul D. Smith	2016	18
7	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model Molecular Cancer Therapeutics ·Chandra Bartholomeusz,Xuemei Xie,Mary Kathryn Pitner,Kimie Kondo,Ali Dadbin,Jangsoon Lee,Hitomi Saso,Paul D. Smith,Kevin N. Dalby,Naoto T. Ueno	2015	59
8	Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport Molecular Cancer Therapeutics ·Becky M. Bola,Amy L. Chadwick,Filippos Michopoulos,Kathryn G. Blount,Brian A. Telfer,Kaye J. Williams,Paul D. Smith,Susan E. Critchlow,Ian J. Stratford	2014	155
9	Inhibition of mTORC1/2 Overcomes Resistance to MAPK Pathway Inhibitors Mediated by PGC1α and Oxidative Phosphorylation in Melanoma Cancer Research ·Y.N. Vashisht Gopal,Helen Rizos,Guo Chen,Wanleng Deng,Dennie T. Frederick,Zachary A. Cooper,Richard A. Scolyer,Gulietta M. Pupo,Kakajan Komurov,Vasudha Sehgal,Jiexin Zhang,Lalit R. Patel,Cristiano Gonçalves Pereira,Bradley M. Broom,Gordon B. Mills,Prahlad T. Ram,Paul D. Smith,Jennifer A. Wargo,Georgina V. Long,Michael A. Davies	2014	148
10	Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells Molecular Cancer Therapeutics ·Weiguo Zhang,Vivian Ruvolo,Gao Chen,Liran Zhou,William G. Bornmann,Twee Tsao,Wendy Schober,Paul D. Smith,Sylvie M. Guichard,Marina Konopleva,Michael Andreeff	2014	30
11	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma Clinical Cancer Research ·Hemant K. Bid,Aaron Kibler,Doris A. Phelps,Sagymbek Manap,Linlin Xiao,Jiayuh Lin,David Capper,Duane Oswald,Brian Geier,Mariko DeWire,Paul D. Smith,Raushan T. Kurmasheva,Xiaokui Mo,Soledad Fernández,Peter J. Houghton	2013	49
12	Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma Clinical Cancer Research ·Marie Cumberbatch,Ximing Tang,Garry Beran,Sonia Eckersley,Xin Wang,Rebecca Ellston,Simon Dearden,Sabina Cosulich,Paul D. Smith,Carmen Behrens,Edward S. Kim,Xinying Su,Shuqiong Fan,Neil Gray,David P. Blowers,Ignacio I. Wistuba,Chris Womack	2013	22
13	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer Clinical Cancer Research ·Radosław Polański,Cassandra L. Hodgkinson,Alberto Fusi,Daisuke Nonaka,Lynsey Priest,Paul A. Kelly,Francesca Trapani,Paul Bishop,Anne White,Susan E. Critchlow,Paul D. Smith,Fiona Blackhall,Caroline Dive,Christopher J. Morrow	2013	282
14	Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055) Cancer Research ·Sarah V. Holt,Armelle Logié,Barry R. Davies,Denis Alférez,Sarah Runswick,Sarah E. Fenton,Christine M. Chresta,Yi Gu,Jingchuan Zhang,Yi‐Long Wu,Robert W. Wilkinson,Sylvie M. Guichard,Paul D. Smith	2012	70
15	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in Braf- Mutant Human Cutaneous Melanoma Cells Cancer Research ·Y.N. Vashisht Gopal,Wanleng Deng,Scott E. Woodman,Kakajan Komurov,Prahlad T. Ram,Paul D. Smith,Michael A. Davies	2010	177
16	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer Clinical Cancer Research ·Udai Banerji,D. Ross Camidge,Henk M.W. Verheul,Roshan Agarwal,Debashis Sarker,Stan B. Kaye,Ingrid M.E. Desar,Johanna N.H. Timmer-Bonte,Sabine Eckhardt,Karl D. Lewis,Kathryn H. Brown,Mireille Cantarini,Clive Morris,Sarah M.A. George,Paul D. Smith,Carla M.L. van Herpen	2010	176
17	Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines Molecular Cancer Therapeutics ·Edward B. Garon,Richard S. Finn,Wylie Hosmer,Judy Dering,Charles Ginther,Shahriar Adhami,Naeimeh Kamranpour,Sharon Pitts,Amrita Desai,David Elashoff,Tim French,Paul D. Smith,Dennis J. Slamon	2010	49
18	The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) Enhances the Radiation Responsiveness of Lung and Colorectal Tumor Xenografts Clinical Cancer Research ·Aoife M. Shannon,Brian A. Telfer,Paul D. Smith,Muhammed Babur,Armelle Logié,Robert W. Wilkinson,Camille Debray,Ian J. Stratford,Kaye J. Williams,Stephen R. Wedge	2009	42
19	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Molecular Cancer Therapeutics ·Barry R. Davies,Armelle Logié,Jennifer S. McKay,Paul Martin,Samantha J. Steele,Richard O. Jenkins,Mark Cockerill,Sue Cartlidge,Paul D. Smith	2007	322
20	Adaptation of nutrient supply to fetal demand in the mouse involves interaction between the Igf2 gene and placental transporter systems Proceedings of the National Academy of Sciences ·Miguel Constância,Emily Angiolini,Ionel Sandovici,Paul D. Smith,Rachel Smith,Gavin Kelsey,Wendy Dean,Anne C. Ferguson‐Smith,Colin P. Sibley,Wolf Reik,Abigail L. Fowden	2005	245

About Paul D. Smith

Paul D. Smith is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 120 papers that have together received 7.5k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (31 papers), Lung Cancer Treatments and Mutations (30 papers), PI3K/AKT/mTOR signaling in cancer (18 papers), Colorectal Cancer Treatments and Studies (15 papers), Cancer Mechanisms and Therapy (13 papers), Epigenetics and DNA Methylation (11 papers), Cancer, Hypoxia, and Metabolism (9 papers) and Genetic Syndromes and Imprinting (7 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (2.4k citations) and Molecular Biology (5.1k citations). Paul D. Smith has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Simon J. Cook, Matthew J. Sale, Elaine Kilgour, Wolf Reik, A. N. Brooks, Christopher J. Caunt, Wendy Dean, Armelle Logié, Nicolas Floc’h and Pasi A. Jänne. Their work appears in journals such as Chemical Reviews, Proceedings of the National Academy of Sciences and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact